臓がん細胞からの細胞外小胞関連マイクロRNA-25-3pは,肝臓のステラ細胞活性化を促進し,がんの進行を促進する
Xuejiao Wu1, Rui Shen2, Zilin Yang3
1Department of Anesthesiology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Biochemical genetics
|August 21, 2025
まとめ
臓がんの転移は,細胞外小胞 (EV) に存在するマイクロRNAであるmiR-25-3pによって引き起こされます. このマイクロRNAは肝臓の星状細胞 (HSC) を活性化し,がんの進行を促進し,予後が悪いことを示します.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- 臓がんは侵襲的で生存率が低いため,診断が遅れて転移することが多い.
- 肝臓の星状細胞 (HSC) の活性化を含む臓がんの転移のメカニズムについては,さらなる解明が必要である.
- 細胞外小胞 (EV) に関連したマイクロRNA (miRNA) が潜在的なバイオマーカーとして出現しています.
研究 の 目的:
- 臓がんの進行と予後に関する新しいバイオマーカーを特定する.
- 臓がんの転移におけるEV関連miRNAの役割を調査する.
- 特定のmiRNAs,HSCの活性化,およびがんの進行の間の機能的リンクを探求する.
主な方法:
- 臓がん患者と対照群におけるEV由来のmiRNAプロフィールの分析
- トランスフェクション,ウェスタン・ブロッティング,免疫光検査,ELISAを含む機能検査.
- miRNA誘発のHSC活性化と,がん細胞の行動に対するその後の影響の評価.
主要な成果:
- miR- 25- 3pは,臓がん患者からのEVで有意に上昇した.
- EVに関連したmiR-25-3pの上昇は,転移の増加と生存率の低下と相関する.
- EV miR- 25- 3pはKLF4を調節することでHSCを活性化させ,VEGFの分泌を促し,がんの進行を強めた.
結論:
- EVに関連したmiR- 25- 3pは,臓がんの進行と予後のための潜在的なバイオマーカーです.
- miR- 25- 3pは,HSCの活性化と臓がんの転移を促進する上で重要な役割を果たします.
- miR-25-3pをターゲットにすることで,臓がんに対する新しい治療戦略が提供される可能性があります.
関連する概念動画
MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K


